Gilead Sciences Stock Surges Despite Trading Volume Drop, Yeztugo Approval Drives Growth

On June 24, 2025, Gilead Sciences Inc. (GILD) experienced a trading volume of $479 million, marking a 44.88% decrease from the previous day. The stock closed at $107.20, reflecting a 0.93% increase from the previous close.

Gilead Sciences, Inc. recently celebrated a significant milestone with the FDA's approval of its twice-yearly HIV prevention injection, Yeztugo. This approval marks a pivotal moment in the history of HIV treatment, as it offers a more convenient and effective prevention method for patients. The company's CEO, Daniel O’Day, highlighted the importance of this development in an interview, emphasizing its potential to revolutionize HIV prevention strategies.

The approval of Yeztugo is expected to drive growth for Gilead Sciences, as it expands the company's portfolio of HIV prevention and treatment options. Analysts from various firms, including Citi and BMO, have praised the approval, with Citi viewing Yeztugo as a key growth driver for the company. BMO described the approval as a 'major win' for Gilead, underscoring its potential to enhance the company's market position in the HIV treatment sector.

Despite the positive news, some analysts remain cautious about the near-term impact of the approval. Oppenheimer, for instance, sees limited near-term effects, suggesting that the full benefits of the approval may take time to materialize. However, the overall sentiment remains optimistic, with many analysts maintaining a buy rating for Gilead Sciences.